stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Nurix Therapeutics, Inc.

United States · NASDAQ: NRIX · Market cap: · P/E: · P/S:

Nurix Therapeutics develops drugs that target and destroy specific proteins inside cells to treat cancer and other diseases.

Nurix Therapeutics is a drug developer with a different idea about how to fight disease. Most medicines work by blocking a protein that is causing trouble — like putting a lock on a door. Nurix instead tries to get rid of the problem protein entirely, using the cell's own garbage-disposal system to break it down and haul it away.

Nurix Therapeutics, Inc. (NRIX) Targeted protein degradation medicines and research collaborations: line art illustration of a scientist in lab coat beside a molecular degrader structure binding a protein
Targeted protein degraders
Nurix makes medicines that use the body's own system to break down harmful proteins.

The cell already has a cleanup crew: a set of enzymes called E3 ligases that tag worn-out or unwanted proteins for destruction. Nurix designs small molecules that grab a target protein and hand it to one of these ligases, essentially tricking the cell into destroying something it normally wouldn't. The company calls this approach targeted protein degradation, and it opens up targets that traditional drugs can't touch. Nurix runs this as two kinds of business. It is developing its own pipeline of experimental drugs, mainly for blood cancers like lymphoma and leukemia, with its most advanced programs in early and mid-stage human trials. It also partners with larger drugmakers — including Gilead Sciences and Sanofi — which pay Nurix upfront, fund the research, and owe it future milestone payments and royalties if drugs succeed. That partnership money is a big reason the company can keep funding its own work; Nurix does not yet sell any approved product, so it loses money and depends on cash from deals and investors.


The bet is a big one. Targeted protein degradation is one of the hotter areas in biotech, and Nurix is among the pioneers, having built a large library of ligases it can use. But drug development is slow, expensive, and full of failure, and the field has attracted competition from other biotech firms and major pharma players building similar programs. For Nurix, the payoff hinges on whether its experimental drugs work in people — and whether its partners stick around to help carry them to market.

Saved answer · last researched 16 Nov 2026